Parabolic growth patterns in 96-well plate cell growth experiments

In Vitro Cellular and Developmental Biology - Animal

Volumn 35, Issue 5, 1999, Pages 270-278

  Faessel, Hélène M ^a   Levasseur, Laurence M ^a   Slocum, Harry K ^a   Greco, William R ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Anticancer drug; Cell culture; MTT; Preclinical pharmacology; Sulforhodamine B; Tissue culture

Indexed keywords

ANTINEOPLASTIC AGENT; DYE;

ADENOCARCINOMA; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CECUM CANCER; GROWTH CURVE; HUMAN; HUMAN CELL; ILEUM CANCER; OVARY CANCER; STAINING; STATISTICAL MODEL;

EID: 0032975502     PISSN: 10712690     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11626-999-0071-z     Document Type: Article

References (12)

1. Alley, M. C.; Scudiero, D. A.; Monks, A., et al. Feasibility of drug screening with panels of human cell lines using a microculture tetrazolium assay. Cancer Res. 48:589-601; 1988.
2. Boyd, M. R.; Paull, K. D. Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen. Drug Dev. Res. 34:91-109; 1995.
3. Crickard, K.; Niedbala, M. J.; Crickard, U., et al. Characterization of human ovarian and endometrial carcinoma cell lines established on extracellular matrix. Gynecol. Oncol. 32:163-173; 1989.
4. Ferron, G. M; Pyszczynski, N. A.; Jusko, W. J. Gender-related assessment of cyclosporin/prednisolone/sirolimus interactions in three human lymphocyte proliferation assays. Transplantation 65:1203-1209; 1997.
5. Grever, M. R.; Schepartz, S. A.; Chabner, B. A. The National Cancer Institute: cancer drug discovery and development program. Semin. Oncol. 19:622-638; 1992.
6. Jamali, M. A. A.; Yin, M.-B.; Mazzoni, A.; Bankusli, I.; Rustum, Y. M. Relationship between cytotoxicity, drug accumulation, DNA damage and repair of human ovarian cancer cells treated with doxorubicin: modulation by the tiapamil analog R011-2933. Cancer Chemother. Pharmacol. 25:77-83; 1989.
7. Levasseur, L.; Faessel, H.; Slocum, H. K.; Greco, W. R. Precision and pattern in 96-well plate growth experiments. Proc. Am. Stat. Assoc. Biopharm. Sect. 227-232; 1995.
8. Levasseur, L. M.; Greco, W. R.; Rustum, Y. M.; Slocum, H. K. Combined-action of paclitaxel and cisplatin against wildtype and resistant human ovarian carcinoma cells. Cancer Chemother. Pharmacol. 40:495-505; 1997.
9. Rogan, A. M.; Hamilton, T. C.; Young, R. C., et al. Reversal of adriamycin resistance by verapamil in human ovarian cancer. Science (Wash DC) 224:994-996; 1984.
10. Rubinstein, L. V.; Shoemaker, R. H.; Paull, K. D., et al. Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J. Natl. Cancer Inst. 82:1113-1118; 1990.
11. Skehan, P.; Storeng, R.; Scudiero, D., et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 82:1107-1112; 1990.
12. Vanhoefer, U.; Shousong, C.; Minderman, H., et al. PAK-104P, a pyridine analogue, reverses paclitaxel and doxorubicin resistance in cell lines and nude mice bearing xenografts that overexpress the multidrug resistance protein. Clin. Cancer Res. 2:369-377; 1996.